Joint pharmacometrics modeling of antimicrobial exposure, biomarkers, and clinical outcome assessments to improve the in silico exploration of dose optimization strategies in critically ill patients KU Leuven
Dosage regimens of antimicrobial drugs predominantly stem from in vitro and animal studies. Critically ill patients display altered, highly variable drug concentration-time profiles in their bodies (i.e., pharmacokinetics; PK). Therefore, therapeutic drug monitoring (TDM) has been used to individualize dosing in this vulnerable patient group. TDM guides dosing based on drug concentration measurements, thereby maximizing the chance to meet ...